NEW YORK (GenomeWeb News) – Leukocare and Trillium Diagnostics today announced a deal to develop and market Leukocare's method for detecting inflammatory activity using circulating cell-free DNA.

Trillium will use the method to develop a commercial assay for diagnosing sepsis, they said. Under the terms of the deal, Leukocare grants Trillium an exclusive, royalty-bearing license to its patent covering the technology and know-how for measuring the quantity of cf-DNA to develop a commercial in vitro diagnostic assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.